Cystic fibrosis drug company to re-engage with HSE on price of Orkambi

Vertex has responded to calls from the HSE with a view to re-engage on the pricing of cystic fibrosis drug Orkambi.

Cystic fibrosis drug company to re-engage with HSE on price of Orkambi

Vertex has responded to calls from the HSE with a view to re-engage on the pricing of cystic fibrosis drug Orkambi.

In a statement this evening, Minister for Health Simon Harris said he is pleased to learn that Vertex has responded to the HSE.

Already a subscriber? Sign in

You have reached your article limit.

Unlimited access. Half the price.

Annual €130 €65

Best value

Monthly €12€6 / month

More in this section

Lunchtime News

Newsletter

Keep up with stories of the day with our lunchtime news wrap and important breaking news alerts.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited